BACKGROUND: The predictors of functional capacity in first episode schizophrenia among seven separable cognitive domains and clinical variables are unknown. AIM: To investigate predictors of functional capacity in first episode schizophrenia and the associations between functional capacity and measures of real-world functioning. METHODS: Socio-demographic, clinical, and cognitive measures from a sample of patients with first episode schizophrenia spectrum disorders aged 18-34years (N=117) were examined at baseline, 4-month follow-up, and 10-month follow-up and used to predict concurrent and longitudinal functional capacity. Symptoms were assessed with the Positive and Negative Syndrome Scale, cognitive functioning with the MATRICS Cognitive Consensus Battery, and functional capacity with the brief version of the University of California San Diego Performance-based Skills Assessment. Linear and logistic regression analyses were adjusted for age, gender, and site. RESULTS:Working memory, negative symptoms, and social cognition accounted for 41% of the variance in functional capacity at baseline. Longitudinally, verbal learning, working memory, and negative symptoms predicted 4-month functional capacity. Working memory and visual learning predicted 10-month functional capacity. Functional capacity was associated to global functioning in the univariate analysis, but in multivariable analyses global functioning, financial independence, and independent living were predicted by negative symptoms or general symptoms explaining 15-23% of the variance. CONCLUSIONS: The strongest single predictor of functional capacity is working memory, followed by negative symptoms. Clinical symptoms, but not functional capacity, predicted real-world functioning. The usability of the UPSA-B in first episode schizophrenia is discussed. Neurocom, ClinicalTrials.gov Identifier: NCT00472862, http://clinicaltrials.gov/ct2/show/NCT00472862?term=neurocom&rank=1.
RCT Entities:
BACKGROUND: The predictors of functional capacity in first episode schizophrenia among seven separable cognitive domains and clinical variables are unknown. AIM: To investigate predictors of functional capacity in first episode schizophrenia and the associations between functional capacity and measures of real-world functioning. METHODS: Socio-demographic, clinical, and cognitive measures from a sample of patients with first episode schizophrenia spectrum disorders aged 18-34years (N=117) were examined at baseline, 4-month follow-up, and 10-month follow-up and used to predict concurrent and longitudinal functional capacity. Symptoms were assessed with the Positive and Negative Syndrome Scale, cognitive functioning with the MATRICS Cognitive Consensus Battery, and functional capacity with the brief version of the University of California San Diego Performance-based Skills Assessment. Linear and logistic regression analyses were adjusted for age, gender, and site. RESULTS:Working memory, negative symptoms, and social cognition accounted for 41% of the variance in functional capacity at baseline. Longitudinally, verbal learning, working memory, and negative symptoms predicted 4-month functional capacity. Working memory and visual learning predicted 10-month functional capacity. Functional capacity was associated to global functioning in the univariate analysis, but in multivariable analyses global functioning, financial independence, and independent living were predicted by negative symptoms or general symptoms explaining 15-23% of the variance. CONCLUSIONS: The strongest single predictor of functional capacity is working memory, followed by negative symptoms. Clinical symptoms, but not functional capacity, predicted real-world functioning. The usability of the UPSA-B in first episode schizophrenia is discussed. Neurocom, ClinicalTrials.gov Identifier: NCT00472862, http://clinicaltrials.gov/ct2/show/NCT00472862?term=neurocom&rank=1.
Authors: Lea Vella; Thomas L Patterson; Philip D Harvey; Margaret McNamara McClure; Brent T Mausbach; Michael J Taylor; Elizabeth W Twamley Journal: Psychiatry Res Date: 2017-06-12 Impact factor: 3.222
Authors: Leslie Marino; Ilana Nossel; Jean C Choi; Keith Nuechterlein; Yuanjia Wang; Susan Essock; Melanie Bennett; Karen McNamara; Sapna Mendon; Lisa Dixon Journal: J Nerv Ment Dis Date: 2015-05 Impact factor: 2.254
Authors: Eric C Meyer; Ricardo E Carrión; Barbara A Cornblatt; Jean Addington; Kristin S Cadenhead; Tyrone D Cannon; Thomas H McGlashan; Diana O Perkins; Ming T Tsuang; Elaine F Walker; Scott W Woods; Robert Heinssen; Larry J Seidman Journal: Schizophr Bull Date: 2014-02-18 Impact factor: 9.306
Authors: Joseph Ventura; Tamara Welikson; Arielle Ered; Kenneth L Subotnik; Richard S E Keefe; Gerhard S Hellemann; Keith H Nuechterlein Journal: Early Interv Psychiatry Date: 2019-06-10 Impact factor: 2.732
Authors: Dean F Salisbury; Nicola R Polizzotto; Paul G Nestor; Sarah M Haigh; Justine Koehler; Robert W McCarley Journal: Schizophr Bull Date: 2017-03-01 Impact factor: 9.306
Authors: A Owoso; C S Carter; J M Gold; A W MacDonald; J D Ragland; S M Silverstein; M E Strauss; D M Barch Journal: Psychol Med Date: 2013-03-25 Impact factor: 7.723
Authors: Junghee Lee; Michael F Green; Monica E Calkins; Tiffany A Greenwood; Raquel E Gur; Ruben C Gur; Laura C Lazzeroni; Gregory A Light; Keith H Nuechterlein; Allen D Radant; Larry J Seidman; Larry J Siever; Jeremy M Silverman; Joyce Sprock; William S Stone; Catherine A Sugar; Neal R Swerdlow; Debby W Tsuang; Ming T Tsuang; Bruce I Turetsky; David L Braff Journal: Schizophr Res Date: 2014-09-22 Impact factor: 4.939